Breaking News Instant updates and real-time market news.

BIIB

Biogen

$335.68

-1.96 (-0.58%)

, PRU

Prudential

$109.09

-0.28 (-0.26%)

10:43
10/17/17
10/17
10:43
10/17/17
10:43

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Buy from Neutral at Mizuho with analyst Thomas Shrader saying he likes what he sees at Biogen again. 2. Prudential (PRU) upgraded to Buy from Neutral at Citi with analyst Suneet Kamath saying Prudential's current valuation does not give the company enough credit for the quality of its business mix. 3. Chevron (CVX) upgraded to Outperform from Neutral at Macquarie with analyst Iain Reid saying cost reduction efforts and new production volumes driving outstanding free cash generation, which should cover capex and the dividend at an oil price below $40/bbl from 2018 onward. 4. Energy Transfer Equity (ETE) upgraded to Buy from Neutral at Goldman Sachs with analyst Theodore Durbin saying he expects Energy Transfer Equity's above average distribution growth to be driven by an improving free cash flow profile. 5. Emerson (EMR) was upgraded to Outperform from Market Perform at Cowen and to Buy from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BIIB

Biogen

$335.68

-1.96 (-0.58%)

PRU

Prudential

$109.09

-0.28 (-0.26%)

CVX

Chevron

$120.19

0.06 (0.05%)

ETE

Energy Transfer Equity

$17.81

0.06 (0.34%)

ETP

Energy Transfer Partners

$18.26

-0.0401 (-0.22%)

EMR

Emerson

$65.68

1.24 (1.92%)

  • 17

    Oct

  • 24

    Oct

  • 27

    Oct

  • 02

    Nov

  • 07

    Nov

  • 09

    Nov

  • 15

    Nov

BIIB Biogen
$335.68

-1.96 (-0.58%)

10/12/17
BMOC
10/12/17
NO CHANGE
Target $130
BMOC
Outperform
AveXis price target raised to $130 from $123 at BMO Capital
BMO Capital analyst M. Ian Somaiya raised the price target on AveXis (AVXS) to $130 and maintained his Outperform rating on the stock. The analyst is moving forward his expectations for the launch of AVXS-101 for Type 1 spinal muscular atrophy by 12 months to the second half of FY18 based on the comparison of event-free survival data suggesting AveXis' product is superior to those of Biogen (BIIB) / Ionis (IONS)'s Spinraza. Somaiya says the end of Phase I meeting in Q4 will confirm an accelerated filing strategy in Type 1 SMA patients.
10/17/17
STFL
10/17/17
UPGRADE
Target $415
STFL
Buy
Biogen upgraded to Buy from Hold at Stifel
Stifel analyst Thomas Shrader upgraded Biogen to Buy and raised his price target for the shares to $415 from $300. The biopharmaceutical company closed yesterday down $1.96 to $335.68. The analyst says he likes what he sees at Biogen again. In a research note titled "MS not imploding, R&D output exploding, Investors should be Reloading," Shrader calls Ocrelizumab a "remarkable drug" that should see a "measured" commercial rollout. Spinraza will eventually be routinely paired with gene therapy while Biogen's large number of additional programs "will increasingly be worth following," the analyst contends. Further, Shrader believes aducanumab's lack of clinical holds suggest that the drug "is safe enough to be used albeit with a slow commercial ramp."
10/17/17
MZHO
10/17/17
UPGRADE
MZHO
Buy
Biogen upgraded to Buy from Neutral at Mizuho
10/17/17
MSCO
10/17/17
NO CHANGE
MSCO
Overweight
Morgan Stanley physician survey points to better than consensus Spinraza sales
Morgan Stanley analyst Matthew Harrison said the firm's survey of 50 physicians suggests that 23% of spinal muscular atrophy patients have had at least one treatment with Biogen (BIIB) and Ionis Pharmaceuticals' (IONS) Spinraza, which he noted is a higher rate than the 18% in Q2 and points to U.S. sales that are 10%-25% ahead of the consensus forecast. Additionally, "essentially all" prescribed patients eventually appear to receive coverage, meaning reimbursement continues to be a minimal headwind for Spinraza, Harrison said. He keeps an Overweight rating on Biogen, which was upgraded at Mizuho and at Stifel this morning.
PRU Prudential
$109.09

-0.28 (-0.26%)

10/10/17
10/10/17
UPGRADE
Target $117

Buy
Prudential upgraded to Buy from Neutral at FBR Capital
FBR Capital analyst Randy Binner upgraded Prudential to Buy and raised his price target for the shares to $117 from $100 ahead of the Q3 reporting season.
10/10/17
10/10/17
DOWNGRADE
Target $52

Neutral
MetLife downgraded to Neutral from Buy at FBR Capital
FBR Capital analyst Randy Binner downgraded MetLife (MET) to Neutral and lowered his price target for the shares to $52 from $53 ahead of the Q3 reporting season. Binner this morning also upgraded Prudential (PRU) to Buy.
10/10/17
10/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Prudential (PRU) upgraded to Buy from Neutral at FBR Capital. 2. RBS (RBS) was upgraded to Neutral from Sell at Citi and to Neutral from Underperform at Credit Suisse. 3. Palo Alto Networks (PANW) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying he sees building traction across the company's portfolio of solutions and he views it as one of the best positioned vendors to execute on an integrated security platform story. 4. Illinois Tool Works (ITW) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying organic growth is likely to be better than forecast in the third quarter. 5. McKesson (MCK) upgraded to Outperform from Market Perform at Cowen with analyst Charles Rhyee saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/17/17
SBSH
10/17/17
UPGRADE
Target $123
SBSH
Buy
Prudential upgraded to Buy from Neutral at Citi
Citi analyst Suneet Kamath upgraded Prudential (PRU) to Buy and raised his price target for the shares to $123 from $110. The analyst also reiterates a Sell rating on MetLife (MET) with an unchanged price target of $47. Prudential's current valuation does not give the company enough credit for the quality of its business mix, Kamath tells investors in a research note. He believes the shares are attractive post the year-to-date underperformance. The analyst also thinks investors will be underwhelmed by Metlife's earnings growth and return on equity post the Brighthouse Financial (BHF) separation.
CVX Chevron
$120.19

0.06 (0.05%)

08/08/17
DBAB
08/08/17
NO CHANGE
DBAB
Deutsche views Pioneer Natural, peers as 'significantly oversold'
Deutsche Bank analyst Ryan Todd believes Pioneer Natural Resources (PXD) as well as the Permian Exploration & Production space are "significantly oversold" following Pioneer's Q2 results last week. The higher gas content of the production stream started an investor debate around the long-term risks to Permian production and resource value, Todd tells investors in a research note. He calls investor fears "wildly overblown" and is a buyer of the group, especially Pioneer Natural. The analyst has Buy ratings on the shares as well as Anadarko Petroleum (APC), ConocoPhillips (COP), Chevron (CVX) and Devon Energy (DVN).
10/03/17
WELS
10/03/17
NO CHANGE
Target $108
WELS
Market Perform
Chevron price target raised to $108 from $100 at Wells Fargo
Wells Fargo analyst Roger Read raised his price target for Chevron to $108 from $100 noting that the company is pursuing its program of standardization, best practices, technology development and application and continuous learning curve efficiencies. The analyst also points out that Chevron is approaching the development of the Permian the way it would a large international project. He reiterates a Market Perform rating on the shares.
10/16/17
WOLF
10/16/17
UPGRADE
WOLF
Outperform
Chevron upgraded to Outperform from Peer Perform at Wolfe Research
10/17/17
MACQ
10/17/17
UPGRADE
Target $135
MACQ
Outperform
Chevron upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Iain Reid upgraded Chevron to Outperform saying cost reduction efforts and new production volumes driving outstanding free cash generation, which should cover capex and the dividend at an oil price below $40/bbl from 2018 onward. The analyst is "very positive" on free cash flow expectations and raised his price target by 29% to $135 on Chevron shares.
ETE Energy Transfer Equity
$17.81

0.06 (0.34%)

07/13/17
STFL
07/13/17
INITIATION
STFL
Buy
Energy Transfer Equity initiated with a Buy at Stifel
Stifel analyst Selman Akyol started coverage of Energy Transfer Equity with a $20 price target and a Buy rating. The analyst predicts that the company's distributable cash flow will jump more than 70% in 2018, and he says that the owner of the Energy Transfer family of companies is "predominately aligned" with Energy Transfer Equity.
10/17/17
GSCO
10/17/17
DOWNGRADE
Target $20
GSCO
Neutral
Energy Transfer Partners downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Theodore Durbin downgraded Energy Transfer Partners (ETP) to Neutral and lowered his price target for the shares to $20 from $25. The analyst sees a weaker distribution growth outlook and prefers Energy Transfer Equity (ETE) over Energy Transfer Partners. He believes Energy Transfer Equity is better positioned to grow free cash flow and drive above average distribution growth. The analyst this morning upgraded Energy Transfer Equity to Buy.
10/17/17
GSCO
10/17/17
UPGRADE
Target $23
GSCO
Buy
Energy Transfer Equity upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Theodore Durbin upgraded Energy Transfer Equity to Buy and raised his price target for the shares to $23 from $22. The analyst expects Energy Transfer Equity's above average distribution growth to be driven by an improving free cash flow profile.
08/30/17
MSCO
08/30/17
UPGRADE
MSCO
Overweight
Dominion Midstream, Hess Midstream Partners upgraded at Morgan Stanley
As previously reported, Morgan Stanley analyst Tom Abrams upgraded Dominion Midstream (DM) and Hess Midstream Partners (HESM), both to Overweight from Equal Weight, as he sees better value in the space after a few months of sector underperformance. He particularly likes equities expected to show higher growth in Distributable Cash Flow per unit, which includes Dominion Midstream and Hess Midstream Partners, he tells investors. Abrams also reiterated his Overweight ratings on Energy Transfer Equity (ETE), Kinder Morgan (KMI), Antero Midstream Partners (AM) and Phillips 66 Partners (PSXP), also citing their valuations relative to their cash flow.
ETP Energy Transfer Partners
$18.26

-0.0401 (-0.22%)

05/19/17
RBCM
05/19/17
DOWNGRADE
Target $20
RBCM
Sector Perform
PennTex downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Elvira Scotto downgraded PennTex Midstream Partners (PTXP) to Sector Perform from Outperform and raised her price target to $20 from $19 to account for Energy Transfer Partners' (ETP) tender offer to purchase all of the outstanding common units.
05/10/17
BERN
05/10/17
UPGRADE
BERN
Outperform
Energy Transfer Equity, Energy Transfer Partners upgraded at Bernstein
As noted earlier, Bernstein upgraded Energy Transfer Equity (ETE) and Energy Transfer Partners (ETP) to Outperform from Market Perform. Analyst Jean Ann Salisbury says that the companies are "arguably levered" to three growth areas: Permian, Marcelllus, and ethane volumes. The analyst adds that several "very positive developments" for the companies have occurred since January: the DAPL project proceeded and its "finish line is in sight; progress was made with the Rover project; the DEP approved Mariner East 2; and 73 rigs were added in the Permian, while oil production there rose meaningfully. Target $23 for Energy Transfer Equity and $30 for Energy Transfer Partners.
05/12/17
WOLF
05/12/17
INITIATION
Target $25
WOLF
Peer Perform
Energy Transfer Partners initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated Energy Transfer Partners with a Peer Perform and a $25 price target.
EMR Emerson
$65.68

1.24 (1.92%)

10/17/17
COWN
10/17/17
UPGRADE
COWN
Outperform
Emerson upgraded to Outperform from Market Perform at Cowen
10/17/17
BOFA
10/17/17
UPGRADE
Target $79
BOFA
Buy
Emerson upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Andrew Obin upgraded Emerson to Buy and increased its price target to $79 from $69 saying shares should trade at a premium relative to peers given strong margins and returns, and accelerating earnings growth. Obin believes Emerson is at the trough of the capex cycle with improved visibility on maintenance, repair, and overhaul spending and said the Commercial & residential Solutions business continues to provide leverage to broader infrastructure/construction spending trends.
09/14/17
JMPS
09/14/17
NO CHANGE
Target $70
JMPS
Outperform
Emerson uncertainty discount unwarranted, says JMP Securities
JMP Securities analyst Joseph Osha noted that July and August are the strongest two-month comps that Emerson Electric has seen in three years and he continues to believe the "uncertainty discount" seen in the share price is unwarranted. The company is seeing continued strength in automation solutions while commercial and residential orders continue to hold steady, said Osha, who reiterates his Outperform rating and $70 price target on Emerson shares.
06/19/17
JMPS
06/19/17
INITIATION
JMPS
Outperform
Emerson initiated with an Outperform at JMP Securities
JMP Securities analyst Joseph Osha started coverage of Emerson with a $70 price target and an Outperform rating. The analyst says that the company is well-managed , "has higher margins than most of its competitors," and "has a solid dividend yield."

TODAY'S FREE FLY STORIES

CAL

Caleres

$30.99

0.05 (0.16%)

16:20
11/21/17
11/21
16:20
11/21/17
16:20
Earnings
Caleres backs FY17 adjusted EPS view $2.10-$2.20, consensus $2.16 »

Backs FY17 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CAL

Caleres

$30.99

0.05 (0.16%)

16:19
11/21/17
11/21
16:19
11/21/17
16:19
Earnings
Caleres reports Q3 EPS 80c, consensus 85c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ALEX

Alexander & Baldwin

$44.87

0.75 (1.70%)

16:18
11/21/17
11/21
16:18
11/21/17
16:18
Hot Stocks
Alexander & Baldwin announces sale of Midstate 99 Distribution Center for $33.4M »

Alexander & Baldwi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDU

MDU Resources

$26.89

0.24 (0.90%)

16:18
11/21/17
11/21
16:18
11/21/17
16:18
Hot Stocks
MDU Resources plans to increment CapEx up to $471M in FY20 »

MDU Resources Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.33

-0.31 (-0.89%)

, TWX

Time Warner

$89.53

1.82 (2.08%)

16:18
11/21/17
11/21
16:18
11/21/17
16:18
General news
On The Fly: Top stock stories for Tuesday »

Stocks opened sharply…

T

AT&T

$34.33

-0.31 (-0.89%)

TWX

Time Warner

$89.53

1.82 (2.08%)

GSK

GlaxoSmithKline

$34.81

-0.31 (-0.88%)

PFE

Pfizer

$35.54

0.19 (0.54%)

UA

Under Armour

$11.37

-0.7 (-5.80%)

UAA

Under Armour

$12.85

-0.59 (-4.39%)

JEC

Jacobs Engineering

$64.86

5.52 (9.30%)

OSUR

OraSure

$16.55

2.59 (18.55%)

CPB

Campbell Soup

$45.84

-4.09 (-8.19%)

DSW

DSW

$19.55

-2.98 (-13.23%)

SIG

Signet Jewelers

$52.79

-23.05 (-30.39%)

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 14

    Dec

GES

Guess

$17.94

0.16 (0.90%)

16:18
11/21/17
11/21
16:18
11/21/17
16:18
Earnings
Guess raises FY18 adjusted EPS view to 56c-63c from 52c-60c, consensus 60c »

Narrows FY18 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

DRE

Duke Realty

$29.30

0.39 (1.35%)

16:17
11/21/17
11/21
16:17
11/21/17
16:17
Hot Stocks
Duke Realty declares 85c per share special dividend »

Duke Realty announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

16:17
11/21/17
11/21
16:17
11/21/17
16:17
Earnings
Breaking Earnings news story on Salesforce »

Salesforce sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

$NSD

NASDAQ Market Internals

16:17
11/21/17
11/21
16:17
11/21/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GES

Guess

$17.94

0.16 (0.90%)

16:17
11/21/17
11/21
16:17
11/21/17
16:17
Earnings
Guess sees Q4 adjusted EPS 48c-55c, consensus 52c »

Sees Q4 revenue growth in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GES

Guess

$17.94

0.16 (0.90%)

16:16
11/21/17
11/21
16:16
11/21/17
16:16
Earnings
Guess reports Q3 adjusted EPS 12c, consensus 12c »

Reports Q3 revenue $554M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

$NYE

NYSE Market Internals

16:16
11/21/17
11/21
16:16
11/21/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVA

Avista

$51.64

-0.19 (-0.37%)

16:14
11/21/17
11/21
16:14
11/21/17
16:14
Hot Stocks
Avista shareholders approve acquisition by Hydro One at $53 per share »

Avista Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AXTA

Axalta Coating

$33.85

0.31 (0.92%)

, AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

16:14
11/21/17
11/21
16:14
11/21/17
16:14
Periodicals
Axalta Coating, AkzoNobel abandon merger talks, WSJ says »

Axalta Coating (AXTA) and…

AXTA

Axalta Coating

$33.85

0.31 (0.92%)

AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.48

1.11 (1.03%)

16:12
11/21/17
11/21
16:12
11/21/17
16:12
Hot Stocks
Salesforce CEO: 'We're on a path to exceed $20 billion' »

"Salesforce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

CRM

Salesforce

$108.58

1.21 (1.13%)

16:11
11/21/17
11/21
16:11
11/21/17
16:11
Hot Stocks
Breaking Hot Stocks news story on Salesforce »

Salesforce reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

HPQ

HP Inc.

$22.45

0.33 (1.49%)

16:10
11/21/17
11/21
16:10
11/21/17
16:10
Hot Stocks
HP Inc. drops 6% in afterhours trading after earnings, guidance »

HP Inc. shares are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CRM

Salesforce

$108.55

1.18 (1.10%)

16:10
11/21/17
11/21
16:10
11/21/17
16:10
Hot Stocks
Salesforce reports deferred revenue $4.39B, up 26% y/y »

Up 24% in constant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

HPE

HP Enterprise

$14.15

0.055 (0.39%)

16:09
11/21/17
11/21
16:09
11/21/17
16:09
Earnings
Breaking Earnings news story on HP Enterprise »

HP Enterprise backs FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

  • 11

    Dec

GME

GameStop

$16.64

0.2 (1.22%)

16:09
11/21/17
11/21
16:09
11/21/17
16:09
Earnings
GameStop sees FY17 EPS $3.10-$3.40, consensus $3.31 »

Sees FY17 comparable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CRM

Salesforce

$108.45

1.0775 (1.00%)

16:09
11/21/17
11/21
16:09
11/21/17
16:09
Earnings
Salesforce sees FY19 revenue $12.45B-$12.5B »

An increase of 19%-20%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

QADB

QAD Inc

$31.74

1.74 (5.80%)

16:08
11/21/17
11/21
16:08
11/21/17
16:08
Earnings
QAD sees FY18 revenue $300M-$302M, consensus $294.59M »

FY18 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.335 (1.51%)

16:08
11/21/17
11/21
16:08
11/21/17
16:08
Hot Stocks
HP Inc. says results demonstrate HP 'strong and getting stronger' »

"Our results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CRM

Salesforce

$108.60

1.24 (1.16%)

16:08
11/21/17
11/21
16:08
11/21/17
16:08
Earnings
Salesforce raises FY18 adjusted EPS view to $1.32-$1.33 from $1.29-$1.31 »

FY18 consensus $1.32.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

HPE

HP Enterprise

$14.16

0.065 (0.46%)

16:08
11/21/17
11/21
16:08
11/21/17
16:08
Hot Stocks
HP Enterprise announces Antonio Neri to replace Meg Whitman as CEO »

Hewlett Packard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.